Inosine Triphosphate (ITP)

Inosine 5'-(tetrahydrogen triphosphate). An inosine nucleotide containing three phosphate groups esterified to the sugar moiety. Synonym: IRPPP.
Also Known As:
ITP; Triphosphate, Inosine; Inosine 5'-(tetrahydrogen triphosphate)
Networked: 3807 relevant articles (285 outcomes, 443 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Bussel, James B: 72 articles (09/2015 - 03/2002)
2. Hou, Ming: 66 articles (06/2015 - 08/2002)
3. Yang, Renchi: 46 articles (11/2015 - 05/2004)
4. Peng, Jun: 39 articles (05/2015 - 06/2003)
5. Godeau, Bertrand: 34 articles (12/2015 - 08/2008)
6. Stasi, Roberto: 32 articles (11/2015 - 11/2002)
7. Michel, Marc: 30 articles (12/2015 - 10/2003)
8. Xue, Feng: 29 articles (11/2015 - 01/2009)
9. Buchanan, George R: 25 articles (12/2015 - 08/2002)
10. Zhang, Lei: 25 articles (11/2015 - 01/2005)

Related Diseases

1. Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
2. Thrombocytopenia (Thrombopenia)
3. Thrombocytopenic Purpura (Thrombopenic Purpura)
4. Hemorrhage
06/01/2014 - "Reaching a consensus for the management of paediatric ITP is further complicated by the lack of a diagnostic test and by the heterogeneity of the disease; for example, although most children remain relatively asymptomatic and go into an early remission, some patients have significant bleeding and others do not go into spontaneous remission. "
04/01/2003 - "The management of the bleeding symptoms without the adverse effects is an important point of steroid medication in ITP after first line treatment."
01/01/2009 - "The present report describes a 73-year-old patient with acute ITP who experienced diffuse alveolar hemorrhage that responded well to high-dose intravenous immunoglobulin therapy combined with corticosteroid pulse therapy."
06/01/1998 - "Suggested areas for study were grouped into five main areas: (i) improved classification of ITP identifying subsets of patients with differing clinical syndromes and response to treatment, and those more likely to have serious bleeding manifestations; identification of patients with reduced thrombopoiesis was emphasized; (ii) studies aimed at elucidating the aetiology and pathophysiology of ITP, with emphasis on distinctions between acute and chronic ITP and between patients responsive or refractory to therapy; these studies focused on measures of humoral and cellular immune dysregulation; (iii) studies of platelet function in ITP, with the intent of defining these abnormalities and correlating them with the clinical manifestations of the disease; (iv) new approaches to treatment, particularly of refractory patients; and (v) a miscellaneous group, which included development of an ITP registry, evaluation of the "burden" of disease, investigation of mood changes in ITP, etc. The discussion was not intended to be all-inclusive, but focused on the content of other talks in this symposium. "
01/01/1988 - "PE combined with IVGG may be a useful treatment for some patients with refractory ITP who have uncontrollable bleeding or require major surgery. "
5. Infection

Related Drugs and Biologics

1. Immunoglobulins (Immunoglobulin)
2. Intravenous Immunoglobulins (IVIG)
3. rituximab (Mabthera)
4. romiplostim
5. eltrombopag
6. RHO(D) antibody (anti-D)
7. Immunoglobulin G (IgG)
8. Prednisolone (Predate)
9. Antibodies
10. Thrombopoietin Receptors

Related Therapies and Procedures

1. Splenectomy
2. Drug Therapy (Chemotherapy)
3. Aftercare (After-Treatment)
4. Transplants (Transplant)
5. Liver Transplantation